Drug intelligence / Profile preview

VNX-203

Development stage: Preclinical
Lead developer: Vironexis Biotherapeutics
Modality: Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

VNX-203 is an investigational AAV-delivered T-cell immuno-gene therapy being developed by Vironexis Biotherapeutics for the treatment of gastric cancer. The therapy is built upon the company's proprietary TransJoin™ platform, which utilizes an adeno-associated virus (AAV) vector to deliver a transgene that programs the patient's own T cells to recognize and eliminate gastric cancer cells in vivo. This approach is designed to provide the therapeutic benefits of T-cell-based immunotherapy while bypassing the logistical and manufacturing complexities associated with traditional ex vivo cell engineering. As of early 2024, VNX-203 is in the discovery stage of development.

Beyond the preview

Go deeper on VNX-203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VNX-203.

Explore the full profile